Please wait while the formulary information is being retrieved.
NAMENDA (MEMANTINE HCL)
- Moderate to severe alzheimer's type dementia
- Namenda Titration Pak Tablets In A Dose Pack
- Namenda Tablet
- Memantine Tablets In A Dose Pack
- Memantine Tablet
- By Indication
Titration Pak 5 mg-10 mg tablets in a dose pack
- by oral route per package directions
10 mg tablet
- 1 tablet (10 mg) by oral route 2 times per day
5 mg tablet
- 2 tablets (10 mg) by oral route 2 times per day
memantine 5 mg-10 mg tablets in a dose pack
- by oral route per package directions
10 mg tablet
- 1 tablet (10 mg) by oral route 2 times per day
5 mg tablet
- 2 tablets (10 mg) by oral route 2 times per day
memantine 10 mg tablet
- 1 tablet (10 mg) by oral route 2 times per day
memantine 5 mg tablet
- 2 tablets (10 mg) by oral route 2 times per day
Moderate to severe alzheimer's type dementia
- by oral route per package directions
- 1 tablet (5 mg) by oral route once daily
- 1 tablet (5 mg) by oral route 2 times per day
- 2 tablets (10 mg) by oral route 2 times per day
- 1 tablet (10 mg) by oral route 2 times per day
- None
Contraindicated
- amantadine HCl
- Ketalar
- ketamine
Severe
Moderate
- acetazolamide
- acetazolamide sodium
- Al hyd-Mg tr-alg ac-sod bicarb
- Alka-seltzer Gold
- Alka-seltzer Heartburn
- Antacid Tablet
- Cytra K Crystals
- Cytra-2
- Cytra-3
- Cytra-k
- Diamox Sequels
- E-z-gas Ii
- Foaming Antacid
- Gaviscon
- K-phos No 2
- K-phos Original
- K-phos-neutral
- methazolamide
- methenamine mand-sod biphos
- Neptazane
- Neut
- Oracit
- Phospha 250 Neutral
- pot & sod citrate-citric acid
- potassium citrate
- potassium citrate-citric acid
- potassium phosphate, monobasic
- potassium&sodium monobas phos
- sod bicarb-citric ac-simeth
- sod phos,di & mono-K phos mono
- sodium & potassium bicarbonate
- sodium acetate
- sodium bicarb & citrate
- sodium bicarbonate
- sodium citrate-citric acid
- sodium lactate
- Taron-crystals
- Tham
- Tricitrates
- tromethamine
- Urocit-k 10
- Urocit-k 15
- Urocit-k 5
- Uroqid-acid No.2
- None
Contraindicated
- Severe renal impairment
Severe
Moderate
- Disease of liver
NAMENDA (MEMANTINE HCL)
- Moderate to severe alzheimer's type dementia
- None
- Acute confusion
- Constipation
- Cough
- Diarrhea
- Dizziness
- Headache disorder
More Frequent
Severe
Less Severe
- Hallucinations
- Hypertension
- Influenza
- Abdominal pain with cramps
- Aggressive behavior
- Back pain
- Depression
- Drowsy
- Fatigue
- Hypotension
- Pain
- Symptoms of anxiety
- Upper respiratory infection
- Urinary incontinence
- Vomiting
- Weight gain
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abnormal hepatic function tests
- Accidental fall
- Acute myocardial infarction
- Acute renal failure
- Agranulocytosis
- Anemia
- Atrial fibrillation
- Atrioventricular block
- Chronic heart failure
- Deep venous thrombosis
- Dyspnea
- Hepatitis
- Leukopenia
- Neutropenic disorder
- Pancreatitis
- Pancytopenia
- Pneumonia
- Prolonged QT interval
- Pulmonary thromboembolism
- Stevens-johnson syndrome
- Suicidal ideation
- Thrombocytopenic disorder
- Thrombotic thrombocytopenic purpura
- Torsades de pointes
Less Severe
- Anorexia
- Bradycardia
- Bronchitis
- Dehydration
- Fecal incontinence
- Fever
- Gait abnormality
- General weakness
- Hyperglycemia
- Insomnia
- Irritability
- Nausea
- Nervousness
- Peripheral edema
- Pharyngitis
- Seizure disorder
- Urinary tract infection
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Memantine
No safety and efficacy established, Not studied in this age range.
No efficacy established in pediatric studies for autism spectrum disorders. Risk of agitation and aggressive behavior.
- 1 Day – 6 Years
- No safety and efficacy established, Not studied in this age range.
- No efficacy established in pediatric studies for autism spectrum disorders. Risk of agitation and aggressive behavior.
- 6 Years – 18 Years
- No safety and efficacy established, Not studied in this age range.
- No efficacy established in pediatric studies for autism spectrum disorders. Risk of agitation and aggressive behavior.
Memantine
- Severity Level:
2
- Additional Notes: Insufficient human data available.
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Memantine
Insufficient human data available
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient human data available |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Memantine
Renal-Adjust dose in severe renal impairment (CrCL< 30 mL/min).
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | Y | N | N | N | N | N |
BEERS: N HEDIS: Y STOPP: Y
No Known Risk
None
- None
| Moderate to severe alzheimer's type dementia | |
| G30 | Alzheimer's disease |
| G30.0 | Alzheimer's disease with early onset |
| G30.1 | Alzheimer's disease with late onset |
| G30.8 | Other alzheimer's disease |
| G30.9 | Alzheimer's disease, unspecified |
| 0-9 | A-Z |
|---|---|
| G30 | Alzheimer's disease |
| G30.0 | Alzheimer's disease with early onset |
| G30.1 | Alzheimer's disease with late onset |
| G30.8 | Other alzheimer's disease |
| G30.9 | Alzheimer's disease, unspecified |
Formulary Reference Tool